Array Biopharma Inc (NASDAQ: ARRY) is off to an incredibly strong start to the trading session this morning, and for good reason. The company reported overwhelmingly strong clinical results, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about the results, what we’re seeing from the stock, and what we’ll be watching for with regard to ARRY ahead.
ARRY Releases Positive Clinical Results
As mentioned above, Array Biopharma is having an incredibly strong start to the trading session in the pre-market hours this morning. Ultimately, the gains are the result of clinical results that were released over the weekend. In a press release issued by the company over the weekend, ARRY released updated results from a 30 patient safety lead-in of the Phase 3 BEACON CRC trial. The trial is designed to evaluate the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody. The triplet combination treatment is being assessed in patients with BRAF-mutant metastatic colorectal cancer whose disease has progressed after one or two prior regimens. The company reported the data at this year’s ASCO Gastrointestinal Cancer Symposium in San Francisco, California.